Made in Chi­na: TaiMed wins FDA OK for a 'break­through' HIV ther­a­py for drug-re­sis­tant pa­tients

The FDA has hand­ed TaiMed and its part­ners at Ther­at­e­ch­nolo­gies an ap­proval for the first new HIV drug to come along in a decade with a nov­el mech­a­nism of ac­tion.

The drug, to be mar­ket­ed as Trog­a­r­zo (ibal­izum­ab-uiyk), works by bind­ing to the sec­ond ex­tra­cel­lu­lar do­main of the CD4+ T cell re­cep­tor, away from oth­er bind­ing sites used by drugs al­ready on the mar­ket. That ap­proach al­lows pa­tients who are be­com­ing re­sis­tant to their ther­a­pies to add this to the mix be­fore be­ing ex­posed to a lethal amount of virus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.